Table 2. Relative risk (RR) of induction of SJS/TEN for associated drugs. Modified according to [15].
|
Drug
Duration of intake |
Patients
n = 379 (%) |
Controls
n = 1,505 (%) |
Univariate RR
(95%CI) |
Multivariate RR
(95%CI) |
Number of cases (%) with intake of “highly suspected” drugs within 8 weeks |
|---|---|---|---|---|---|
| Acidic acid NSAIDs3 ≤ 8 weeks > 8 weeks |
27 (7.1) 24 3 |
21 (1.4) 11 10 |
5.4 (3.0 – 10) 9.2 (4.5 – 19) 1.2 (0.3 – 4.4) |
5.6 (2.6 – 12) 13 (5.2 – 31) 0.7 (0.1 – 3.3) |
7 (26%) 7 (29%) 0 |
| Macrolides4 | 18 (4.8) | 10 (0.7) | 7.5 (3.4 – 16) | 6.8 (2.6 – 18) | 8 (44%) |
| Quinolones5 | 13 (3.4) | 5 (0.3) | 10.7 (3.8 – 30) | 6.9 (1.8 – 27) | 6 (46%) |
| Cephalosporines6 | 19 (5.0) | 7 (0.5) | 11.3 (4.7 – 27) | 7.3 (2.4 – 22) | 12 (63%) |
| Tetracyclines7 | 7 (1.9) | 5 (0.3) | 5.6 (1.8 – 18) | 6.3 (1.6 – 25) | 1 (14%) |
| Aminopenicillins8 | 18 (4.8) | 18 (1.2) | 4.1 (2.1 – 8.0) | 2.4 (1.0 – 5.9) | 10 (56%) |
3including diclofenac (21,17), indomethacin (1,2), lonazolac (2,0), etodolac (1,1), aceclofenac (1,0), sulindac (1,0), ketorolac (0,1); 4including azithromycin (3,1), clarithromycin (4,5), erythromycin (3,0), midecamycin (0,1), pristinamycin (1,0), roxithromycin (4,2), spiramycin (3,1); 5including ciprofloxacin (6,2), grepafloxacin (1,0), levofloxacin (1,0), norfloxacin (4,2), ofloxacin (1,1); 6including cefaclor (0,2), cefalexin (3,0), cefapirin (1,0), cefatrizine (2,0), cefixime (3,2), cefonicide (1,2), cefotiam (2,0), cefpodoxim (0,2), ceftibutem (0,1), ceftriaxon (3,0), cefuroxim (5,0); 7including doxycycline (3,5), metacycline (1,0), minocycline (3,0); 8including amoxicillin (17,18), bacampicillin (1,0).